Dudediligence.

Korro Bio, Inc

KRRONASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$0.00Sep ’24$2.3MDec ’24$2.5MMar ’25$1.5MJun ’25$1.1MSep ’25$1.3MDec ’25$0.00Mar ’26$0.00Jun ’26
Net income, by quarter
−$21.0MSep ’24−$21.2MDec ’24−$23.4MMar ’25−$25.8MJun ’25−$18.1MSep ’25−$50.0MDec ’25−$19.6MMar ’26−$18.9MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$14.1M$0.00$0.00$2.3M$6.4M
Operating income−$84.0M−$59.0M−$84.5M−$91.9M−$121.9M
Net income−$84.7M−$58.0M−$81.2M−$83.6M−$117.3M
Operating cash flow−$76.1M−$53.6M−$67.3M−$60.1M−$78.6M
Free cash flow−$79.0M−$58.8M−$75.1M−$78.0M−$79.1M
Cash$79.6M$36.3M$166.2M$55.6M$21.8M
Debt$833,000$10.0Mnone on filenone on filenone on file
Shares outstanding34.6M268.5K8.0M9.4M9.4M